IL11RA: Interleukin-11 receptor subunit alpha
Receptor for interleukin-11 (IL11).
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on IL11RA, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| OprelvekinBoxed warning | Approved | Mabwell (Shanghai) Bioscience Co., Ltd. | Protein or peptide | AgonistInterleukin 11 receptor alpha agonist | 5 |
- Craniosynostosis and dental anomalies0.78
- Thrombocytopenia0.49
- Craniosynostosis0.46
- Craniosynostosis syndrome, autosomal recessive0.46
- Neoplasm0.40
- Autoimmune disorder of central nervous system0.23
- Acute leukemia0.18
- Protozoa infectious disease0.11
- Von Willebrand disease (hereditary or acquired)0.10
- Lung adenocarcinoma0.10
- Glioblastoma0.09
- Non-Hodgkin lymphoma0.09
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2050, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q14626, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets